Search - tctmd.com

Displaying 61 - 80 of 615

Sort: Relevancy | Date

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

News Conference News ESC 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

September 10, 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

News Conference News ESC 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

September 06, 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

September 02, 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Dropping Aspirin From Post-LAAO Regimens Seems Like a Good Idea

News Daily News

Dropping Aspirin From Post-LAAO Regimens Seems Like a Good Idea

August 27, 2024

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

Scientific Statement Reviews Current Antithrombotic Options in PAD

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

August 26, 2024

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

News Daily News

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

August 21, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

Post-TAVI Neurologic Problems an Ongoing Issue

News Daily News

Post-TAVI Neurologic Problems an Ongoing Issue

August 16, 2024

Ideal Aspirin Dose in Secondary Prevention Doesn’t Differ Much by Sex

News Daily News

Ideal Aspirin Dose in Secondary Prevention Doesn’t Differ Much by Sex

July 11, 2024

Case-based Treatment of a Patient With Dyspnea and Increasing Transvalvular Gradients

Presentation NY Valves 2024

Case-based Treatment of a Patient With Dyspnea and Increasing Transvalvular Gradients

Presenter: Nino Mihatov

June 07, 2024

How to Define and Manage Subclinical Leaflet Thrombosis

Presentation NY Valves 2024

How to Define and Manage Subclinical Leaflet Thrombosis

Presenter: Hasan Jilaihawi

June 07, 2024

Histopathology From Explanted Valves in Patients With HALT and RLM

Presentation NY Valves 2024

Histopathology From Explanted Valves in Patients With HALT and RLM

Presenter: Stephanie Sellers

June 07, 2024

Arial View of Antithrombotic Therapy Post TAVR

Presentation NY Valves 2024

Arial View of Antithrombotic Therapy Post TAVR

Presenter: Thomas Pilgrim

June 07, 2024

Valve Thrombosis and Antithrombotic Therapy After Surgical and Transcatheter Mitral Valve Replacement: A Systematic Review and Meta-Analysis

Presentation NY Valves 2024

Valve Thrombosis and Antithrombotic Therapy After Surgical and Transcatheter Mitral Valve Replacement: A Systematic Review and Meta-Analysis

Presenter: Mark Zorman

June 06, 2024

Medicare Analysis Suggests Benefit of PFO Closure Beyond Age 60

News Conference News ESOC 2024

Medicare Analysis Suggests Benefit of PFO Closure Beyond Age 60

May 17, 2024

Site-specific antithrombotic therapy: DESyne BDS Plus study 12-month outcomes

Presentation EuroPCR 2024

Site-specific antithrombotic therapy: DESyne BDS Plus study 12-month outcomes

Presenter: Alexandre Abizaid

May 14, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.